Highest-materiality recent filing
Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027
Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M
FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
Lyell Immunopharma appoints Smital Shah as Chief Financial and Business Officer
Smital Shah appointed CFO and principal financial officer, effective March 9, 2026.
Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH
In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
Lyell Immunopharma amends bylaws to modernize shareholder proposals and align with DGCL
Removed requirement for nominated directors to provide support information except on independence.
Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR
Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.
Upfront $40M cash + 1.9M Lyell shares; up to $820M in milestones plus tiered royalties up to 10% on US net sales.
Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
Lyell Immunopharma CFO Charles Newton resigns effective Oct 31, 2025
Charles Newton resigns as CFO and principal financial/accounting officer, effective October 31, 2025.
Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share
Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.
Lyell Immunopharma to issue 625,000 shares upon achieving CAR T-cell clinical milestone
Milestone for ImmPACT's next-gen CAR T-cell candidate achieved on June 20, 2025.
Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL
In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
Lyell Immunopharma appoints Mark Bachleda to Board, expanding size to 8
Board increased from 7 to 8 directors; Mark Bachleda, Pharm.D., M.B.A., appointed as Class I director effective June 9, 2025.
Lyell Immunopharma announces 1-for-20 reverse stock split effective May 30, 2025
Reverse split at 1-for-20 ratio; effective 5:00 p.m. ET on May 30, 2025.
Class I director Catherine Friedman elected with 156.3M votes for (96.3% of votes cast).
on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.
Max materiality 0.85 · Median 0.68 · Most common event other_material